Presentations by Program

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Rana K, Wunderink R, Tsuei B, Rahav G, Kovalchuk E, Koksal I, Maloney K and Srinivasan S (IDWeek 2020)

Sulbactam-Durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

McLeod S, Moussa S, Hackel M, and Miller A (IDWeek 2020)

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug Resistant (MDR) Mycobacterium abscessus (Mab)

Dousa KM, Kurz SG, Bethel CR, Taracilla M, Miller AA and Bonomo RA (IDWeek 2020)

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

An Adventure in Antibacterial Drug Discovery - Competing Methyl Effects on Biochemical Potency and Cell Accumulation

Tommasi R (BAARN 2020)

In Vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

McLeod SM, Mathur T, Hackel M, Wise M, Morrissey I and Miller AA (IDWeek 2019)

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Miller AA, O'Donnell JP, Lane DJ, Panchal RG and Mueller JP (IDWeek 2019)

Discovery of a Novel Series of Penicillin-binding Protein 3 Inhibitors to Treat Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Durand-Reville T, Wu X, Guler S, Zhang J, Comita-Prevoir J, Sylvester M, Romero J, Velez-Vega C, Wu F, Iyer R, Shapiro A, Moussa S, Carter N, Chen A, McLeod S, O'Donnell J, Miller A and Tommasi R (ASM ESCMID 2019)

Resistance to Sulbactam-Durlobactam in Clinical Isolates of Acinetobacter baumannii is Rare and Maps to PBP3

Moussa S, Shapiro AB, McLeod SM and Miller AA (Acinetobacter 2019)

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

McLeod S, Carter N, Moussa S, Mueller J, Tommasi R and Miller A (Microbe 2019)